Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Action agonists, stimulants, modulators |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MAMLD1 modulators(mastermind like domain containing 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Leukemia | Preclinical | United States | 05 Nov 2025 |






